Aspen says profit rose notably in its year to end-June
Earnings per share could rise as much as 37%, with the company also getting a lift from asset sales
SA’s biggest pharmaceutical maker, Aspen Pharmacare, has flagged a profit rise of at least a fifth for its year to end-June, also reporting it has seen an expected improvement in a manufacturing business hit by supply-chain disruptions.
Normalised headline earnings per share (HEPS) from continuing operations are expected to rise between 20% and 25% to as much as 1,637.2c to end-June, the group said in a short trading update, while earnings per share could rise as much as 37%...
Would you like to comment on this article?
Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
This article is reserved for HeraldLIVE subscribers.
A subscription gives you full digital access to all our content.
Already subscribed? Simply sign in below.
Already registered on DispatchLIVE, BusinessLIVE, TimesLIVE or SowetanLIVE? Sign in with the same details.
Questions or problems? Email helpdesk@heraldlive.co.za or call 0860 52 52 00.